The Russian Direct Investment Fund (RDIF) applied for registration of the Sputnik V vaccine in the European Union. The examination process is expected to start in February.
“The RDIF has applied to register the vaccine and expects it to be reviewed in February. Based on the examinations, the European Medical Agency will decide on the registration of Sputnik V in the EU”, the vaccine Twitter reported.
On January 19, more than 20 experts from the European Medicines Agency (EMA) held a scientific consultation for the developers of the Sputnik V vaccine. Recommendations on the results of the discussion will be sent to vaccine developers within 7-10 days. The decision of EMA to provide Sputnik V registration will be based on the results of a series of expert inspections.
On January 22, the World Health Organization (WHO) will start the pre-submission review of the Sputnik V registration application.
The anti-COVID-19 vaccine Sputnik V was developed by the Gamalei Center. It is already registered in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan.
